ATE178092T1 - Methode zur selektion spezifischer bakteriophagen - Google Patents

Methode zur selektion spezifischer bakteriophagen

Info

Publication number
ATE178092T1
ATE178092T1 AT95903485T AT95903485T ATE178092T1 AT E178092 T1 ATE178092 T1 AT E178092T1 AT 95903485 T AT95903485 T AT 95903485T AT 95903485 T AT95903485 T AT 95903485T AT E178092 T1 ATE178092 T1 AT E178092T1
Authority
AT
Austria
Prior art keywords
phage
pct
molecule
protein
selecting specific
Prior art date
Application number
AT95903485T
Other languages
English (en)
Inventor
Carl A K Borrebaeck
Marta Duenas
Original Assignee
Bioinvent Int Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioinvent Int Ab filed Critical Bioinvent Int Ab
Application granted granted Critical
Publication of ATE178092T1 publication Critical patent/ATE178092T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT95903485T 1993-12-06 1994-12-05 Methode zur selektion spezifischer bakteriophagen ATE178092T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9304060A SE9304060D0 (sv) 1993-12-06 1993-12-06 Sätt att selektera specifika bakteriofager

Publications (1)

Publication Number Publication Date
ATE178092T1 true ATE178092T1 (de) 1999-04-15

Family

ID=20392016

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95903485T ATE178092T1 (de) 1993-12-06 1994-12-05 Methode zur selektion spezifischer bakteriophagen

Country Status (12)

Country Link
US (1) US5712089A (de)
EP (1) EP0739413B1 (de)
JP (1) JP3574135B2 (de)
AT (1) ATE178092T1 (de)
AU (1) AU686292B2 (de)
CA (1) CA2178205A1 (de)
DE (1) DE69417446T2 (de)
DK (1) DK0739413T3 (de)
ES (1) ES2132601T3 (de)
GR (1) GR3030210T3 (de)
SE (1) SE9304060D0 (de)
WO (1) WO1995016027A1 (de)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750373A (en) * 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
GB9500851D0 (en) * 1995-01-17 1995-03-08 Bionvent International Ab Method of selecting specific bacteriophages
SE9503151D0 (sv) * 1995-09-13 1995-09-13 Bioinvent Internatioal Ab Combined ligand and receptor display
SE506771C2 (sv) * 1996-02-06 1998-02-09 Gotpat 105 Ab Fusionsprotein, bakteriofag uttryckande proteinet, dessas användning samt hybridoma celler och monoklonaler producerade av cellerna
US6174915B1 (en) 1997-03-25 2001-01-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US6497874B1 (en) 1997-02-05 2002-12-24 Maardh Sven Recombinant phages
GB9716900D0 (en) * 1997-08-08 1997-10-15 Bioinvent Int Ab Method for selecting phage displaying ligand binders
EP1518927A3 (de) * 1998-02-11 2005-06-22 Maxygen, Inc. Optimisierung von Immunmodulierungsfähigkeiten von genetischen Impfstoffe
CA2320626A1 (en) * 1998-02-11 1999-08-19 Maxygen, Inc. Genetic vaccine vector engineering
US7153655B2 (en) * 1998-06-16 2006-12-26 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
EP1100890A2 (de) 1998-07-27 2001-05-23 Genentech, Inc. Verbesserung der transformationseffizienz in phagendisplay durch abänderung des hüllproteins
US20030180714A1 (en) * 1999-12-15 2003-09-25 Genentech, Inc. Shotgun scanning
NZ521540A (en) 2000-04-11 2004-09-24 Genentech Inc Multivalent antibodies and uses therefor
US6686154B2 (en) 2000-06-05 2004-02-03 Zyomyx, Inc. Screening of phage displayed peptides without clearing of the cell culture
AU2001279055A1 (en) 2000-07-27 2002-02-13 Genentech, Inc. Apo-2L receptor agonist and CPT-11 synergism
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US6958213B2 (en) 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
US20020086292A1 (en) 2000-12-22 2002-07-04 Shigeaki Harayama Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules
US7262012B2 (en) * 2002-05-17 2007-08-28 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function using varied exonuclease digestion in two polynucleotide populations
WO2004035537A2 (en) 2002-10-16 2004-04-29 Euro-Celtique S.A. Antibodies that bind cell-associated ca 125/o772p and methods of use thereof
GB2400851B (en) * 2003-04-25 2004-12-15 Bioinvent Int Ab Identifying binding of a polypeptide to a polypeptide target
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
US20060292554A1 (en) * 2004-05-18 2006-12-28 Genentech, Inc. Major coat protein variants for C-terminal and bi-terminal display
GB2432366B (en) * 2005-11-19 2007-11-21 Alligator Bioscience Ab A method for in vitro molecular evolution of protein function
ES2524312T3 (es) 2008-03-14 2014-12-05 Allergan, Inc. Ensayos de actividad de serotipo A de toxina botulínica de base inmunológica
KR20110031343A (ko) 2008-06-20 2011-03-25 와이어쓰 엘엘씨 베타-용혈성 스트렙토코커스 균주로부터 유래된 ｏｒｆ1358을 사용하는 조성물 및 방법
MX2011001409A (es) 2008-08-14 2011-03-29 Cephalon Australia Pty Ltd Anticuerpos anti-il-12/il-23.
CA3059768A1 (en) * 2008-09-05 2010-03-11 President And Fellows Of Harvard College Continuous directed evolution of proteins and nucleic acids
SG174353A1 (en) 2009-03-13 2011-11-28 Allergan Inc Immuno-based retargeted endopeptidase activity assays
CA2807244A1 (en) * 2010-08-27 2012-03-01 University Of Zurich A novel diagnostic and therapeutic target in inflammatory and/or cardiovascular diseases
AU2011348204B2 (en) 2010-12-22 2017-03-02 President And Fellows Of Harvard College Continuous directed evolution
GB201200259D0 (en) 2012-01-09 2012-02-22 Ohlin Per M Novel therapies
EP2970917A2 (de) 2013-03-15 2016-01-20 Altria Client Services LLC Bakteriophage und verfahren zur herstellung und verwendung
EP3077417A1 (de) 2013-12-08 2016-10-12 Peptcell Limited Hiv-antigene und antikörper und zusammensetzungen, verfahren und verwendungen davon
MX369173B (es) 2013-12-24 2019-10-30 Janssen Pharmaceutica Nv Anticuerpos y fragmentos anti-vista.
US10179911B2 (en) 2014-01-20 2019-01-15 President And Fellows Of Harvard College Negative selection and stringency modulation in continuous evolution systems
US10920208B2 (en) 2014-10-22 2021-02-16 President And Fellows Of Harvard College Evolution of proteases
WO2016123427A1 (en) 2015-01-29 2016-08-04 Altria Client Services Llc Bacteriophage and methods of using
WO2016123425A1 (en) 2015-01-29 2016-08-04 Altria Client Services Llc Endolysin from bacteriophage against geobacillus and methods of using
WO2016168631A1 (en) 2015-04-17 2016-10-20 President And Fellows Of Harvard College Vector-based mutagenesis system
BR112017027870A2 (pt) 2015-06-24 2018-08-28 Janssen Pharmaceutica Nv anticorpos e fragmentos anti-vista
US10392674B2 (en) 2015-07-22 2019-08-27 President And Fellows Of Harvard College Evolution of site-specific recombinases
US11524983B2 (en) 2015-07-23 2022-12-13 President And Fellows Of Harvard College Evolution of Bt toxins
WO2017019895A1 (en) 2015-07-30 2017-02-02 President And Fellows Of Harvard College Evolution of talens
BR112018016461A2 (pt) 2016-02-12 2019-10-01 Janssen Pharmaceutica Nv anticorpos e fragmentos anti-vista, usos dos mesmos e métodos de identificação dos mesmos
US10765724B2 (en) 2016-03-29 2020-09-08 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-IL12/23 antibody
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
AU2017336799B2 (en) 2016-09-30 2023-08-31 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-IL23 specific antibody
EP3312290A1 (de) 2016-10-18 2018-04-25 Ipsen Biopharm Limited Zellulärer vamp-spaltungstest
MX2019005661A (es) 2016-11-16 2019-10-07 Janssen Biotech Inc Método para tratar la psoriasis con el anticuerpo específico anti-il23.
EP3573658A4 (de) 2017-01-30 2021-07-21 Janssen Biotech, Inc. Anti-tnf-antikörper, zusammensetzungen und verfahren zur behandlung von aktiver psoriatischer arthritis
JP2020506947A (ja) 2017-02-07 2020-03-05 ヤンセン バイオテツク，インコーポレーテツド 活動性強直性脊椎炎を治療するための抗ｔｎｆ抗体、組成物、及び方法
US11447809B2 (en) 2017-07-06 2022-09-20 President And Fellows Of Harvard College Evolution of tRNA synthetases
WO2019056002A1 (en) 2017-09-18 2019-03-21 President And Fellows Of Harvard College CONTINUOUS EVOLUTION FOR STABILIZED PROTEINS
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
WO2019150309A1 (en) 2018-02-02 2019-08-08 Hammack Scott Modulators of gpr68 and uses thereof for treating and preventing diseases
WO2019171252A1 (en) 2018-03-05 2019-09-12 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
US11913044B2 (en) 2018-06-14 2024-02-27 President And Fellows Of Harvard College Evolution of cytidine deaminases
JP2021530697A (ja) 2018-07-18 2021-11-11 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で治療した後の持続応答予測因子
CA3113837C (en) 2018-09-24 2022-07-12 Janssen Biotech, Inc. Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody
EP3883607A4 (de) 2018-11-20 2022-08-17 Janssen Biotech, Inc. Sicheres und effizientes verfahren zur behandlung von psoriasis mit anti-il-23-spezifischem antikörper
MA54562A (fr) 2018-12-18 2021-10-27 Janssen Biotech Inc Méthode sûre et efficace de traitement du lupus avec un anticorps anti-il12/il23
WO2020148651A1 (en) 2019-01-15 2020-07-23 Janssen Biotech, Inc. Anti-tnf antibody compositions and methods for the treatment of juvenile idiopathic arthritis
US20220064278A1 (en) 2019-01-23 2022-03-03 Janssen Biotech, Inc. Anti-TNF Antibody Compositions for Use in Methods for the Treatment of Psoriatic Arthritis
MA55282A (fr) 2019-03-14 2022-01-19 Janssen Biotech Inc Procédés de fabrication pour la production de compositions d'anticorps anti-tnf
KR20210141990A (ko) 2019-03-14 2021-11-23 얀센 바이오테크 인코포레이티드 항-il12/il23 항체 조성물을 생성하기 위한 제조 방법
EP3938391A1 (de) 2019-03-14 2022-01-19 Janssen Biotech, Inc. Verfahren zur herstellung von anti-tnf-antikörperzusammensetzungen
EA202192508A1 (ru) 2019-03-14 2022-03-29 Янссен Байотек, Инк. Способы получения композиций антитела к фно
MA55383A (fr) 2019-03-18 2022-01-26 Janssen Biotech Inc Méthode de traitement du psoriasis chez des sujets pédiatriques avec un anticorps anti-il12/il23
CN113874073A (zh) 2019-05-23 2021-12-31 詹森生物科技公司 用针对IL-23和TNFα的抗体的联合疗法治疗炎性肠病的方法
JP2022535534A (ja) 2019-06-03 2022-08-09 ヤンセン バイオテツク，インコーポレーテツド 活動性強直性脊椎炎を治療するための抗ｔｎｆ抗体、組成物、及び方法
EP3976648A1 (de) 2019-06-03 2022-04-06 Janssen Biotech, Inc. Anti-tnf-antikörperzusammensetzungen und verfahren zur behandlung von aktiver psoriasis-arthritis
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
CA3212729A1 (en) 2021-03-12 2022-09-15 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
JP2024510588A (ja) 2021-03-12 2024-03-08 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体による、ｔｎｆ療法に対する不十分な応答を有する乾癬性関節炎患者を治療する方法
IL309987A (en) 2021-07-09 2024-03-01 Janssen Biotech Inc Production methods for the production of anti-IL12/IL23 antibody compositions
EP4367137A1 (de) 2021-07-09 2024-05-15 Janssen Biotech, Inc. Herstellungsverfahren zur herstellung von anti-tnf-antikörperzusammensetzungen
KR20240034218A (ko) 2021-07-09 2024-03-13 얀센 바이오테크 인코포레이티드 항-tnf 항체 조성물을 생산하기 위한 제조 방법
IL312401A (en) 2021-10-29 2024-06-01 Janssen Biotech Inc Methods for treating Crohn's disease with a specific anti-IL23 antibody
CA3238377A1 (en) 2021-11-15 2023-05-19 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
CA3239216A1 (en) 2021-11-23 2023-06-01 Janssen Biotech, Inc. Method of treating ulcerative colitis with anti-il23 specific antibody
US20230312703A1 (en) 2022-03-30 2023-10-05 Janssen Biotech, Inc. Method of Treating Psoriasis with IL-23 Specific Antibody
WO2023223265A1 (en) 2022-05-18 2023-11-23 Janssen Biotech, Inc. Method for evaluating and treating psoriatic arthritis with il23 antibody
US20240199734A1 (en) 2022-11-22 2024-06-20 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4122599C2 (de) * 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
EP0614989A1 (de) * 1993-02-17 1994-09-14 MorphoSys AG Verfahren für in vivo Selektion von Ligandenbindende Proteine

Also Published As

Publication number Publication date
AU686292B2 (en) 1998-02-05
JP3574135B2 (ja) 2004-10-06
ES2132601T3 (es) 1999-08-16
US5712089A (en) 1998-01-27
DE69417446D1 (de) 1999-04-29
GR3030210T3 (en) 1999-08-31
AU1252195A (en) 1995-06-27
DK0739413T3 (da) 1999-10-11
EP0739413A1 (de) 1996-10-30
EP0739413B1 (de) 1999-03-24
DE69417446T2 (de) 1999-09-02
CA2178205A1 (en) 1995-06-15
WO1995016027A1 (en) 1995-06-15
SE9304060D0 (sv) 1993-12-06
JPH09506000A (ja) 1997-06-17

Similar Documents

Publication Publication Date Title
ATE178092T1 (de) Methode zur selektion spezifischer bakteriophagen
DK0523395T3 (da) Seroreaktive områder på proteinerne E1 og E2 i HPV 16
NO964650D0 (no) LAG-3 protein-opplöselige polypeptidfraksjoner, fremgangsmåte for fremstilling, teraupeutisk preparat og anti-idiotype antistoff
ATE301471T1 (de) Verwendung von antikörpen gegen cd45ro leukozytenantigen zur immunmodulation
WO1999062526A3 (en) Use of genetically engineered antibodies to cd38 to treat multiple myeloma
ATE169058T1 (de) Gegen cd3 gerichtete antikörper
DK0503648T3 (da) CD2-bindingsdomæne af lymfocytfunktion-associeret antigen 3
ATE253593T1 (de) Immunglobulin-superfamilie domainen und fragmente mit erhöhter löslichkeit
BR9804826A (pt) Proteìna de fusão antigênica portando epìtopos galoc 1,3 gal
NZ512083A (en) Methods of increasing lean tissue mass using OB protein compositions
DK0626861T3 (da) Behandling af astma.
DE69614510T2 (de) Verbesserte methode zur selektion spezifischer bakteriophagen
WO1999003987A3 (fr) Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie
HUP0103650A2 (hu) Vírusburok-proteinek epitópjai és az ellenük termelt ellenanyagok alkalmazása HCV-vírusantigén gazdaszövetből történő kimutatására
GR3018371T3 (en) Method for identifying or determining proteins and applications therefor.
NZ305083A (en) Use of cd40 binding proteins (a cd40 ligand or monoclonal antibody that specifically binds to cd40) for stimulating a immune response
DE69607034T2 (de) Pcna bindende substanz
CA2126182A1 (en) Humanized antibodies reactive with gpiib/iiia
EP0725081A4 (de) MONOKLONALER ANTIKÖRPER GEGEN MxA DES MENSCHLICHEN Mx PROTEINS
DE3765822D1 (de) Material fuer affinitaetschromatographie und dessen anwendung zur trennung und reinigung von proteinischen antigenen von bakterien des genus bordetella.
ATE328088T1 (de) Transketolase-verwandtes protein
KR890009417A (ko) 모노크로날 항체의 제조방법 및 그것의 이용방법
DK0597043T3 (da) Porcine adipocytantigener og deres anvendelse til immunologisk bekæmpelse af fedt
GB2333295A (en) Modified protein G and fragments thereof
IT1267667B1 (it) Metodo per il dosaggio di una variante della proteina alfa-1-antitripsina

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee